Samay Jain, MD
Urology · Port Orchard, WANPI 1679505515
Payments from drug & device makers
Across 9 payments — averaging $48.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Covidien LP$161
- Procept Biorobotics Corporation$151
- Merck$32
- Laborie Medical Technologies Corp.$24
- Endo Pharmaceuticals Inc.$22
- Endo USA, Inc.$17
- plus $25 from 2 others
What the payments were for
- Food & beverage$433100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Covidien LP | 1 | $161 |
| Procept Biorobotics Corporation | 1 | $151 |
| Merck | 2 | $32 |
| Laborie Medical Technologies Corp. | 1 | $24 |
| Endo Pharmaceuticals Inc. | 1 | $22 |
| Endo USA, Inc. | 1 | $17 |
| Boston Scientific | 1 | $17 |
| Profound Medical Corp. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LigaSure$161
- AquaBeam Robotic System$151
How this compares
$433 in reported general payments places this provider in the 25th percentile of 274 urology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 13 | $10,307 |
| ElmironPentosan Polysulfate Sodium | 12 | $9,438 |
| Finasteride | 643 | $8,366 |
| Tamsulosin Hcl | 498 | $6,763 |
| Oxybutynin Chloride ErOxybutynin Chloride | 311 | $5,909 |
| Estradiol | 48 | $4,259 |
| Potassium Citrate ErPotassium Citrate | 26 | $4,025 |
| Methenamine Hippurate | 50 | $3,910 |
| Testosterone | 17 | $3,570 |
| Testosterone Cypionate | 44 | $3,215 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 13 | $1,434 |
| NitrofurantoinNitrofurantoin Macrocrystal | 30 | $1,171 |
| Trospium Chloride | 11 | $909 |
| Sodium ChlorideSodium Chloride Irrig Solution | 25 | $907 |
| Oxybutynin Chloride | 25 | $648 |
Paid to pharmacies, not to this prescriber.
Other urology in Port Orchard
- James PorterSeattle$2.6M
- Shane PearceSpokane$1.8M
- Raymond LanceSpokane$1.2M
- Jonathan WrightSeattle$1M
- Thomas WalshSeattle$388K
- Una LeeSeattle$236K
- Marah HehemannSeattle$213K
- Sarah PsutkaSeattle$185K
- Alvaro LucioniSeattle$152K
- Karny JacobyMountlake Terrace$122K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.